NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CA-23-087 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-274 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.
Funding Opportunity RFA-AG-24-046 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) aims toprovide a proof-of-principle for a novel strategy for Alzheimer Disease and Alzheimer Related Dementias (AD/ADRD) immunotherapies. Specifically, the goal is to examine if a novel immunotherapeutic approach in cancer immunotherapy with Chimeric Antigen Receptor (CAR) immune cellscould be customized as treatments for AD/ADRD. This NOFO utilizes the R61/R33Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities.
Notice NOT-CA-23-081 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-23-290 from the NIH Guide for Grants and Contracts. The purpose of this funding announcement is to invite proposals focused on developing strategies and interventions to improve diagnostic safety in the heterogenous ambulatory care environment. AHRQ is interested in providing support designed to develop, test, and evaluate ambulatory care activities that will improve diagnostic safety and quality.
Notice NOT-DK-23-030 from the NIH Guide for Grants and Contracts
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)
Funding Opportunity PA-23-263 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Funding Opportunity PA-23-291 from the NIH Guide for Grants and Contracts. The purpose of this funding announcement is to invite proposals focused on understanding and improving diagnostic safety in the heterogenous ambulatory care environment. AHRQ is interested in learning the incidence and contributory factors of diagnostic error within and across the array of ambulatory care services.
Notice NOT-DA-25-025 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-24-069 from the NIH Guide for Grants and Contracts. The intersection of criminal-legal and community-based health systems is a critical target for addressing the overdose crisis. To support research on effective interventions and implementation strategies, the National Institute on Drug Abuse intends to continue the Justice Community Overdose Innovation Network (JCOIN) Phase II. The purpose of the network is to bring together a national consortium of investigators and practitioner partners to conduct an array of research and capacity building activities to address the overdose epidemic among individuals involved in the criminal-legal system. The structure of the network shall consist of three highly integrated components - (1) Research Hubs; (2) a single, central Coordination and Translation Center; and (3) a single, central Methodology and Advanced Analytics Resource Center. This NOFO solicits applications for a Coordination and Translation Center. This NOFO runs in parallel with a companion NOFO for the Methodology and Advanced Analytics Resource Center (NOT-DA-24-068); a NOFO for Research Hubs is anticipated at a future date (NOT-DA-25-025).
Funding Opportunity RFA-DA-24-068 from the NIH Guide for Grants and Contracts. The intersection of justice and community-based health systems is a critical target for addressing the opioid crisis. The National Institute on Drug Abuse intends to establish the Justice Community Overdose Innovation Network (JCOIN) using the cooperative agreement mechanism. The purpose of the network is to establish a national consortium of investigators examining promising interventions and other approaches that can improve the capacity of the justice system to effectively respond to the opioid epidemic. The structure of the network shall consist of three highly integrated components - (1) Clinical Research Centers (each center will propose a study to be executed in at least 5 research performance sites); (2) a single, central Coordination and Translation Center; and (3) a single, central Methodology and Advanced Analytics Resource Center. This FOA solicits applications for a Methodology and Advanced Analytics Resource Center. This FOA runs in parallel with companion FOAs that seek applications for Clinical Research Centers (RFA-DA-19-025), and a single Coordination and Translation Center (RFA-DA-19-024).
Notice NOT-CA-23-084 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-25-018 from the NIH Guide for Grants and Contracts. The goal of this concept is to support exploratory research and preliminary interventions to address the interrelated and compounding contextual factors that contribute to substance use and HIV risk among sexual trafficking survivors. This would be accomplished through research that builds new interventions and models of care that can effectively engage ST survivors in care for SUD, HIV, trauma, and other mental health outcomes and addresses key structural and social determinants of health that contribute to risk for ST as well as barriers to and facilitators of escaping continued exploitation.
Notice of Changes of PAR-21-314 "Blueprint MedTech: Incubator Hubs (U54 Clinical Trial Not Allowed)"
Notice NOT-EB-23-016 from the NIH Guide for Grants and Contracts
Notice NOT-CA-23-086 from the NIH Guide for Grants and Contracts
Notice NOT-GM-23-053 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-23-042 from the NIH Guide for Grants and Contracts. The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers.
Notice NOT-OH-23-003 from the NIH Guide for Grants and Contracts
Notice NOT-DA-23-036 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-253 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs.